TSX Venture Exchange: NVC
VANCOUVER, Feb. 22, 2012 /CNW/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies used to treat vascular disease, today announced that the company will participate in the Lazard Capital Markets Annual Medical Technology and Life Sciences/Tools Snowbird Conference. The event is being held at the Snowbird Resort in Snowbird, UT February 29-March 2, 2012.
The conference format consists of one-on-one meetings between participating companies and institutional investors. Investors interested in meeting with Neovasc should contact Lazard Capital Markets directly.
About Neovasc Inc.
Neovasc Inc. is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™ for the treatment of refractory angina, the Tiara™ technology in development for the transcatheter treatment of mitral valve disease and a line of advanced biological tissue products that are used as key components in a variety of third-party medical products, such as vascular surgical patches and transcatheter heart valves. For more information, visit: www.neovasc.com.
For further information: